

1 Thinner cortex is associated with psychosis onset in 2 individuals at Clinical High Risk for Developing 3 Psychosis: An ENIGMA Working Group mega- 4 analysis

5
6 Short Title: Cortical Thickness in CHR

7 8 Authors

9
10 **Jalbrzikowski, Maria**; Hayes, Rebecca A.; Wood, Stephen J.; Nordholm, Dorte; Zhou, Juan H.;
11 Fusar-Poli, Paolo; Uhlhaas, Peter J.; Takahashi, Tsutomu; Sugranyes, Gisela; Kwak, YooBin;
12 Mathalon, Daniel H.; Katagiri, Naoyuki; Hooker, Christine I.; Smigielski, Lukasz; Colibazzi,
13 Tiziano; Va, Esther; Tang, Jinsong; Koike, Shinsuke; Rasser, Paul E.; Michel, Chantal;
14 Lebedeva, Irina; ten Velden Hege Istad, Wenche; de la Fuente-Sandoval, Camilo; Waltz, James
15 A.; Mizrahi, Romina R.M.; Corcoran, Cheryl; Resch, Franz; Tamnes, Christian K.; Haas,
16 Shabaila S.; Lemmers-Jansen, Imke L.J.; Agartz, Ingrid; Allen, Paul; Andreassen, Ole A.;
17 Atkinson, Kimberley; Bachman, Peter; Baeza, Inmaculada; Baldwin, Helen; Bartholomeusz, Cali
18 F.; Brønnevik, Kolbjørn S.; Catalano, Sabrina; Chee, Michael W.L.; Chen, Xiaogang; Cho, Kang
19 Ik K.; Cooper, Rebecca E.; Copley, Vanessa L.; Dolz, Montserrat; Ebdrup, Bjørn H.; Fortea,
20 Adriana; Glenthøj, Louise B.; Glenthøj, Birte Y.; de Haan, Lieuwe; Hamilton, Holly K.; Harris,
21 Mathew A.; Haut, Kristen M.; He, Ying; Heekeren, Karsten; Heinz, Andreas; Hubl, Daniela;
22 Hwang, WuJeong; Kaess, Michael; Kasai, Kiyoto; Kim, Minah; Kindler, Jochen; Klaunig,
23 Mallory, J.; Kristensen, Tina D.; Kwon, Jun Soo; Lawrie, Stephen M.; Lee, Jimmy; León-Ortiz,
24 Pablo; Lin, Ashleigh; Loewy, Rachel L.; Ma, Xiaoqian; Mathalon, Daniel H.; McGorry, Patrick;
25 McGuire, Philip; Mizuno, Masafumi; Møller, Paul; Moncada-Habib, Toma; Muñoz-Samons,
26 Daniel; Nelson, Barnaby; Nemoto, Takahiro; Nordentoft, Merete; Omelchenko, Maria A.;
27 Opedal, Ketil; Ouyang, Lijun; Pantelis, Christos; Pariente, Jose C.; Raghava, Jayachandra;
28 Reyes-Madrugal, Francisco; Roach, Brian J.; Rössberg, Jan I.; Rössler, Wulf; Salisbury, Dean F.;
29 Sasabayashi, Daiki; Schall, Ulrich; Schiffman, Jason; Schlagenhaut, Florian; Schmidt, Andre;
30 Sørensen, Mikkel E.; Suzuki, Michio; Theodoridou, Anastasia; Tomyshev, Alexander S.; Tor,
31 Jordina; Vaernes, Tor G.; Velakoulis, Dennis; Venegoni, Gloria D.; Vinogradov, Sophia;
32 Wenneberg, Christina; Westlye, Lars T.; Yamasue, Hidenori; Yuan, Liu; Yung, Alison R.; van
33 Amelsvoort, Thérèse A.M.J.; Turner, Jessica A.; van Erp, Theo G.M.; Thompson, Paul M.; Hernaes,
34 Dennis.

35 36 Author Affiliations

37
38 Amsterdam UMC, Amsterdam, The Netherlands (de Haan); Arkin, Amsterdam, The Netherlands
39 (de Haan); Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research,
40 CINS, Mental Health Centre Glostrup, University of Copenhagen, Glostrup, Denmark (Ebdrup,
41 Glenthøj, Sørensen, Kristensen); Center for Evolutionary Cognitive Sciences, Graduate School
42 of Art and Sciences, The University of Tokyo (Koike); Center for Sleep and Cognition, Yong Loo
43 Lin School of Medicine, National University of Singapore, Singapore (Zhou); Center for the
44 Neurobiology of Learning and Memory, 309 Qureshey Research Lab, Irvine, CA, USA (Van
45 Erp); Center for Translational Magnetic Resonance Research, Yong Loo Lin School of
46 Medicine, National University of Singapore, Singapore (Zhou); Centre for Clinical Intervention
47 and Neuropsychiatric Schizophrenia Research (CINS), Glostrup, Denmark (Raghava); Centre
for Mental Health, Faculty of Health, Arts and Design, School of Health Sciences, Swinburne

48 University, Melbourne, Australia (Pantelis, Cropley); Centre for Neuropsychiatric Schizophrenia
49 Research, CNSR, Glostrup, Denmark (Raghava); Centre for Sleep and Cognition, Yong Loo Lin
50 School of Medicine, National University of Singapore, Singapore (Chee); Centre for Youth
51 Mental Health, University of Melbourne, Australia (Wood, Bartholomeusz, Nelson); Child and
52 Adolescent Mental Health Research Group, Institut de Recerca Sant Joan de Déu, Barcelona,
53 Spain (Via, Dolz, Muñoz-Samons, Tor); Child and Adolescent Psychiatry and Psychology
54 Department, Hospital Sant Joan de Déu, Barcelona, Spain (Via, Dolz Abadia, Muñoz-Samons,
55 Tor); Clinic for Child and Adolescent Psychiatry, University Hospital of Heidelberg, Heidelberg,
56 Germany (Resch); Clinical Translational Neuroscience Laboratory, Department of Psychiatry
57 and Human Behavior, University of California Irvine, Irvine, CA, USA (Van Erp); Columbia
58 University Department of Psychiatry, New York, USA (Colibazzi); Copenhagen Research
59 Center for Mental Health - CORE, Mental Health Center Copenhagen, Copenhagen University
60 Hospital, Denmark (Nordholm, Glenthøj, Kristensen, Nordentoft, Wenneberg); Department for
61 Mental Health Research and Development, Division of Mental Health and Addiction, Vestre
62 Viken Hospital Trust, Norway (Møller); Department of Brain and Behavioral Sciences, University
63 of Pavia, Italy (Fusar-Poli); Department of Brain and Cognitive Sciences, Seoul National
64 University College of Natural Sciences, Republic of Korea (Kwak, Hwang); Department of Child
65 and Adolescent Psychiatry and Psychology, Institute of Neuroscience, Hospital Clinic
66 Barcelona, Fundació Clínic Recerca Biomèdica, Universitat de Barcelona, Spain (Fortea);
67 Department of Child and Adolescent Psychiatry and Psychology, Institute of Neuroscience,
68 Hospital Clinic Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS),
69 CIBERSAM, Universitat de Barcelona, Spain (Sugranyes, Baeza); Department of Child and
70 Adolescent Psychiatry, Psychiatric University Hospital Zurich, University of Zurich, Switzerland
71 (Smigielski); Department of Child and Adolescent Psychiatry, Center of Psychosocial Medicine,
72 University of Heidelberg, Heidelberg, Germany (Kaess); Department of Child and Adolescent
73 Psychiatry, Charité Universitätsmedizin, Berlin, Germany (Uhlhaas); Department of Clinical
74 Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark
75 (Ebdrup, Glenthøj); Department of Clinical Physiology, Nuclear Medicine and PET, Functional
76 Imaging Unit, Glostrup, Denmark (Raghava); Department of Neuropsychiatry, Graduate School
77 of Medicine, The University of Tokyo, Japan (Kasai); Department of Neuropsychiatry, Seoul
78 National University Hospital, Republic of Korea (Kim, Kwon); Department of Neuropsychiatry,
79 Toho University School of Medicine, Japan (Katagiri, Mizuno, Nemoto); Department of
80 Neuropsychiatry, University of Toyama Graduate School of Medicine and Pharmaceutical
81 Sciences, Toyama, Japan (Takahashi, Sasabayashi, Suzuki); Department of Pharmacology and
82 Toxicology, University of Toronto, Canada (Koppel); Department of Psychiatric Research,
83 Diakonhjemmet Hospital, Oslo, Norway (Agartz); Department of Psychiatry & Behavioral
84 Sciences, University of California, San Francisco, CA, USA (Hamilton); Department of
85 Psychiatry & Neuropsychology, School for Mental Health and Neuroscience, Maastricht
86 University, The Netherlands (van Amelsvoort, Hernaus); Department of Psychiatry (UPK),
87 University of Basel, Switzerland (Borgwardt, Schmidt); Department of Psychiatry and
88 Behavioral Sciences, Rush University Medical Center, Chicago IL (Hooker); Department of
89 Psychiatry and Psychotherapy I, LVR-Hospital Cologne, Cologne, Germany
90 (Heekeren); Department of Psychiatry and Psychotherapy, Charité – Universitätsmedizin Berlin,
91 corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin
92 Institute of Health, Germany (Heinz, Schlagenhauf); Department of Psychiatry and
93 Psychotherapy, Charité Universitätsmedizin, Berlin, Germany (Rössler); Department of
94 Psychiatry and Psychotherapy, University of Lübeck, Germany (Borgwardt); Department of
95 Psychiatry, Hamamatsu University School of Medicine, Hamamatsu City, Japan (Yamasue);
96 Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA
97 (Corcoran, Haas); Department of Psychiatry, Psychiatry Neuroimaging Laboratory, Brigham and
98 Women's Hospital, Harvard Medical School, Boston, MA, USA (Cho); Department of Psychiatry,

99 Psychotherapy and Psychosomatics, Psychiatric University Hospital Zurich, University of Zurich,
100 Switzerland (Smigielski, Heekeren, Rössler, Theodoridou); Department of Psychiatry, Rush
101 University Medical Center, Chicago, IL, USA (Haut); Department of Psychiatry, Seoul National
102 University College of Medicine, Republic of Korea (Kim, Kwon); Department of Psychiatry, Sir
103 Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
104 (Tang); Department of Psychiatry, the Second Xiangya Hospital, Central South University,
105 Changsha, Hunan, China (Chen, He, Ma, Ouyang, Yuan); Department of Psychiatry, University
106 of California, San Francisco, CA, USA (Mathalon, Loewy, Roach); Department of Psychiatry,
107 University of Edinburgh, UK (Atkinson, Harris); Department of Psychiatry, University of
108 Minnesota, MN, USA (Vinogradov); Department of Psychiatry, University of Pittsburgh, PA, USA
109 (Jalbrzikowski, Hayes, Bachman, Catalano, Salisbury); Department of Psychological Science,
110 University of California, Irvine, CA, USA (Schiffman); Department of Psychology, University of
111 Maryland, Baltimore County, MD, USA (Klaunig, Schiffman); Department of Psychology,
112 University of Oslo, Norway (Westlye); Department of Psychology, University of Roehampton,
113 London, UK (Allen); Department of Psychosis Studies, Institute of Psychiatry, Psychology and
114 Neuroscience, King's College London, UK (Lemmers-Jansen, Baldwin); Department of
115 Psychosis, Institute of Mental Health, Singapore (Lee); Division of Psychiatry, University of
116 Edinburgh, Edinburgh, UK (Lawrie, Venegoni); Douglas Research Center, Montreal, Canada
117 (Mizrahi); Early Intervention in Psychosis Advisory Unit for South-East Norway, TIPS Sør-Øst,
118 Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway (Værnes); EPIC
119 Lab, Department of Psychosis Studies, King's College London, UK (Fusar-Poli); Faculty of
120 Behavioural and Movement sciences, Department of Clinical, Neuro and Developmental
121 Psychology, Vrije Universiteit Amsterdam, The Netherlands (Lemmers-Jansen); Faculty of
122 Social Sciences, University of Stavanger, Norway (Hegelstad); Florey Institute of Neuroscience
123 and Mental Health, Australia (Pantelis); Georgia State University, Atlanta, GA, USA (Turner);
124 Hunan Key Laboratory of Psychiatry and Mental Health, Changsha, Hunan, China (Ouyang,
125 Yuan, Yung); Imaging Genetics Center, Mark & Mary Stevens Institute for Neuroimaging &
126 Informatics, Keck USC School of Medicine, Los Angeles, CA, USA (Thompson); Institute of
127 Neuroscience and Psychology, University of Glasgow, Glasgow, UK (Uhlhaas); James J Peters
128 VA, Bronx, NY, USA (MIRECC) (Corcoran); Key Laboratory of Medical Neurobiology of
129 Zhejiang Province, Zhejiang, China (Tang); King's College London, UK (McGuire); Laboratory of
130 Experimental Psychiatry, Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico
131 (de la Fuente-Sandoval, León-Ortiz, Moncada-Habib, Reyes-Madrigal); Lee Kong Chian School
132 of Medicine, Nanyang Technological University, Singapore (Lee); Maastricht University, The
133 Netherlands (Venegoni); Magnetic Resonance Imaging core facility, Institut d'Investigacions
134 Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain (Pariante); Maryland Psychiatric
135 Research Center, University of Maryland School of Medicine, MD, USA (Waltz); McGill
136 University, Montreal, Canada (Mizrahi); Melbourne Neuropsychiatry Centre, Department of
137 Psychiatry, University of Melbourne & Melbourne Health, Melbourne, Australia (Cooper,
138 Cropley, Velakoulis); Mental Health Research Center, Moscow, Russia (Lebedeva,
139 Omelchenko, Tomyshev); National Clinical Research Center for Geriatric Disorders, Xiangya
140 Hospital, Central South University, Changsha, China (Chen, Ouyang, Yuan, Yung);
141 Neuropsychiatry, The Royal Melbourne Hospital, Australia (Velakoulis); New York State
142 Psychiatric Institute, NY, USA (Colibazzi); NIHR Maudsley Biomedical Research Centre (South
143 London and Maudsley NHS Foundation Trust & King's College London), UK (Baldwin);
144 NORMENT, Division of Mental Health and Addiction, Oslo University Hospital & Institute of
145 Clinical Medicine, University of Oslo, Oslo, Norway (Tamnes, Agartz, Andreassen, Røssberg,
146 Værnes, Westlye); Orygen, The University of Melbourne, Melbourne, Australia (Wood,
147 Bartholomeusz, McGorry, Nelson, Yung); Priority Centre for Brain & Mental Health Research,
148 The University of Newcastle, Australia
149 (Rasser, Schall); Priority Research Centre for Stroke and Brain Injury, The University of
Newcastle, Australia (Rasser); Priority Research Centre Grow Up Well, The University of

150 Newcastle, Australia (Schall); PROMENTA Research Center, Department of Psychology,
151 University of Oslo, Norway (Tamnes); Psychosis Studies, Institute of Psychiatry, Psychology
152 and Neuroscience, King's College London, UK (Allen); Research Center for Idling Brain
153 Science, University of Toyama, Toyama, Japan (Takahashi, Sasabayashi, Suzuki); San
154 Francisco Veterans Affairs Health Care System, San Francisco, CA (Hamilton); School of
155 Psychology, University of Birmingham, UK (Wood); Stavanger Medical Imaging Laboratory
156 (SMIL), Stavanger University Hospital, Norway (Oppedal); Telethon Kids Institute, The
157 University of Western Australia, Perth, Australia (Lin); The University of Tokyo Institute for
158 Diversity and Adaptation of Human Mind (UTIDAHM), Japan (Koike, Kasai); TIPS Network for
159 Clinical Research in Psychosis, Stavanger University Hospital, Norway (Hegelstad);
160 Translational Research Center, University Hospital of Psychiatry and Psychotherapy, University
161 of Bern, Bern, Switzerland (Hubl); University Hospital of Child and Adolescent Psychiatry and
162 Psychotherapy, University of Bern, Bern, Switzerland (Michel, Kaess, Kindler)
163
164

165 **Key words:** magnetic resonance imaging, cortical thickness, ultra high-risk for psychosis,
166 prodromal, schizophrenia, at-risk mental states, gray matter, brain volume, CHR, clinical high
167 risk

168

169 **Address for Correspondence**

170 3501 Forbes Ave, Suite 430

171 Pittsburgh, PA, United States of America, 15213

172 jalbrzikowskime@upmc.edu/dennis.hernaus@maastrichtuniversity.nl

173 Word Count (Total): 3413 (including Key Points, Abstract, and Main Text)

174 Word Count (Abstract): 332 (max 350)

175 Word Count (Body): 2961 (max 3000)

176 Tables: 1 main text/20 supplemental

177 Figures: 3 main text/5 supplemental

178 Citation no.: 123

179

180 **Key Points**

181
182 **Question:** How do baseline brain morphometric features relate to later psychosis conversion in
183 individuals at clinical high risk (CHR)?

184 **Findings:** In the largest coordinated international analysis to date, reduced baseline cortical
185 thickness, but not cortical surface area or subcortical volume, was more pronounced in CHR, in
186 a manner highly consistent with thinner cortex in established psychosis. Regions that displayed
187 greater cortical thinning in future psychosis converters additionally displayed abnormal
188 associations with age.

189 **Meaning:** CHR status and later transition to psychosis is robustly associated with reduced cortical
190 thickness. Abnormal age associations and specificity to cortical thickness may point to aberrant
191 postnatal brain development in CHR, including pruning and myelination.

192 **Abstract**

193

194 **Importance:** The ENIGMA clinical high risk for psychosis (CHR) initiative, the largest pooled
195 CHR-neuroimaging sample to date, aims to discover robust neurobiological markers of
196 psychosis risk in a sample with known heterogeneous outcomes.

197

198 **Objective:** We investigated baseline structural neuroimaging differences between CHR
199 subjects and healthy controls (HC), and between CHR participants who later developed a
200 psychotic disorder (CHR-PS+) and those who did *not* (CHR-PS-). We assessed associations
201 with age by group and conversion status, and similarities between the patterns of effect size
202 maps for psychosis conversion and those found in other large-scale psychosis studies.

203

204 **Design, Setting, and Participants.** Baseline T1-weighted MRI data were pooled from 31
205 international sites participating in the ENIGMA CHR Working Group. MRI scans were processed
206 using harmonized protocols and analyzed within a mega- and meta-analysis framework from
207 January-October 2020.

208

209 **Main Outcome(s) and Measure(s):** Measures of regional cortical thickness (CT), surface area
210 (SA), and subcortical volumes were extracted from T1-weighted MRI scans. Independent
211 variables were group (CHR, HC) and conversion status (CHR-PS+, CHR-PS-, HC).

212

213 **Results:** The final dataset consisted of 3,169 participants (CHR=1,792, HC=1,377, age range:
214 9.5 to 39.8 years, 45% female). Using longitudinal clinical information, we identified CHR-PS+
215 (N=253) and CHR-PS- (N=1,234). CHR exhibited widespread thinner cortex compared to HC
216 (average $d=-0.125$, range: -0.09 to -0.17), but not SA or subcortical volume. Thinner cortex in
217 the fusiform, superior temporal, and paracentral regions was associated with psychosis
218 conversion (average $d=-0.22$). Age showed a stronger negative association with left fusiform
219 and left paracentral CT in HC, compared to CHR-PS+. Regional CT psychosis conversion effect
220 sizes resembled patterns of CT alterations observed in other ENIGMA studies of psychosis.

221

222 **Conclusions and Relevance:** We provide evidence for widespread subtle CT reductions in
223 CHR. The pattern of regions displaying greater CT alterations in CHR-PS+ were similar to those
224 reported in other large-scale investigations of psychosis. Additionally, a subset of these regions
225 displayed abnormal age associations. Widespread CT disruptions coupled with abnormal age
226 associations in CHR may point to disruptions in postnatal brain developmental processes.

227

228 1. INTRODUCTION

229 The clinical high-risk paradigm is a widely used framework to investigate mechanisms
230 underlying psychosis vulnerability. Help-seeking individuals who do not meet diagnostic criteria
231 for a psychotic disorder, but typically present with subthreshold psychotic symptoms and
232 accumulating risk factors, are considered at clinical high-risk (CHR) for developing psychosis¹⁻³.
233 An estimated 18-20% of CHR individuals develop a psychotic disorder within 2 years of
234 identification⁴, although conversion rates vary⁵⁻¹¹, likely due to heterogeneous recruitment and
235 sampling strategies, and interventions applied^{2,13}. However, despite decades of research, the
236 nature of morphometrical alterations associated with psychosis conversion remains largely
237 unknown. Here, we aim to address this question by combining all available structural
238 neuroimaging data in CHR to date, in an attempt to better understand brain mechanisms
239 associated with psychosis risk and conversion in this population.

240 A large body of work has used structural magnetic resonance imaging (sMRI) to
241 investigate morphometric brain alterations in CHR individuals¹⁴⁻³⁷. However, the extent to which
242 characteristic baseline structural neuroimaging differences exist between those at CHR who
243 later develop a psychotic disorder (CHR-PS+) compared to those who do *not* (CHR-PS-) is
244 debated. Many studies failed to find baseline differences between CHR-PS+ and CHR-PS-
245 ^{15,35,38,39}, though a meta-analysis and multi-center study found lower prefrontal and temporal
246 volumes or cortical thickness (CT) in CHR-PS+^{40,41}. High attrition rates in CHR samples⁴²⁻⁴⁴,
247 coupled with low psychosis conversion rates^{4,45}, often yield insufficient power to detect between-
248 group structural brain differences. Moreover, small sample sizes can be associated with inflated
249 effect sizes^{46,47}, so effect sizes of prior studies that found structural brain alterations in CHR may
250 be overestimated. Although multi-site consortia aim to address these challenges^{34,48-50}, the
251 largest published sMRI studies to date included fewer than 50 CHR-PS+^{38,41}. Furthermore, it is
252 currently unknown whether group differences are robust enough to predict outcomes.

253 Importantly, many CHR participants are adolescents or young adults, a timeframe
254 associated with psychosis onset^{51,52}. Several brain regions implicated in psychosis show
255 protracted developmental courses continuing through adolescence⁵³⁻⁶³, suggesting that
256 morphometric alterations associated with psychosis risk vary with age. Indeed, there are
257 developmental influences on psychotic symptom presentation⁶⁴⁻⁶⁸, perhaps driven by
258 differences in regional brain changes. It is not fully understood how age-related patterns in brain
259 morphometry in CHR differ from normal development. Thus, using a developmental framework
260 to examine whether morphometric alterations in CHR are influenced by age may provide
261 important insights into mechanisms associated with psychosis risk, and the stability of
262 neuroimaging measures associated with psychosis risk across development.

263 Finally, it is unknown whether baseline brain alterations associated with future
264 conversion to psychosis resemble those observed in other large-scale psychosis studies.
265 Understanding whether morphometric alterations in CHR overlap with those observed in
266 individuals who have schizophrenia⁶⁹⁻⁷¹ and individuals with a genetic subtype of psychosis^{72,73}
267 will provide insights into convergent or distinct alterations across the psychosis spectrum.

268 To address these questions, we founded the Enhancing Neuro Imaging Genetics
269 through Meta-Analysis (ENIGMA) Clinical High Risk Working Group in 2018. Using baseline

270 sMRI data and longitudinal clinical information from 31 sites, this study addressed the following
271 questions:

- 272 1. Do CHR and healthy control (HC) participants differ in CT, surface area (SA),
273 and/or subcortical volumes?
- 274 2. Is there a neuroanatomic signature associated with future transition to a
275 psychotic disorder (CHR-PS+ versus CHR-PS- versus HC)?
- 276 3. Do structural neuroimaging measures identified in Aims 1 and 2 display group
277 differences in age associations, suggestive of abnormal developmental
278 trajectories?
- 279 4. Is the pattern of morphometric alteration associated with psychosis conversion
280 similar to that observed in ENIGMA studies of psychosis?

281

282

283 **2. METHODS**

284

285 **Participants**

286 We included 1,792 CHR and 1,377 HC from 31 sites participating in the ENIGMA CHR Working
287 Group (Table 1). CHR data consisted of CHR-PS+ (N=253), CHR-PS- (N=1,234), and CHR
288 individuals without follow-up data (CHR-UNK, N=305). CHR participants met CAARMS (N=821)
289 or SIPS (N=971) CHR criteria (see details in Supplement). Site-specific inclusion/exclusion
290 criteria are detailed in **eTable 1**. All sites obtained Institutional Review Board approval prior to
291 data collection. Informed written consent was obtained from every participant or the participant's
292 guardian (for participants <18 years). All studies were conducted in accordance with the
293 Declaration of Helsinki⁷⁴.

294

295 **Image Acquisition and Processing**

296 Thirty-one sites contributed T1-weighted MRI brain scans from 50 MRI scanners (**eTable**
297 **2** for MRI acquisition details). We conducted power calculations to estimate the sample size
298 necessary to detect statistically significant effects (see **Supplement** for details).

299 We extract structural gray matter measures of 68 CT, 68 SA measures, and 16
300 subcortical volume measures using the FreeSurfer analysis software⁷⁵⁻⁷⁸. We implemented the
301 ENIGMA consortium quality assessment pipeline^{70,73,79-82} (**Supplement** for further details).

302 Prior to conducting the mega-analysis, all neuroimaging data were adjusted for scanner
303 protocol effects using neuroComBat⁸³, a modified version of ComBat⁸⁴ that increases the
304 statistical power and precision of neuroimaging effect size estimates⁸³.

305

306

307 **Statistical Analyses**

308

309 *Group and conversion-related differences in structural neuroimaging metrics*

310 We assessed group differences using general linear models (GLMs) within a mega-
311 analysis framework, with each sMRI measure (i.e., regional CT, SA or subcortical volume) as
312 the dependent variable and group (HC/CHR) or conversion status (CHR-PS+/CHR-PS-/HC) as

313 the independent variable. We included age, age², sex, and estimated total intracranial volume
314 (ICV) as covariates in all models, and corrected for multiple comparisons (N=155) using the
315 False Discovery Rate (FDR⁸⁵) method. We considered q -values<0.05 statistically significant.

316 For all structural neuroimaging measures, we conducted pairwise comparisons and
317 calculated Cohen's d effect sizes between two (CHR vs. HC) or three groups of interest (CHR-
318 PS+ vs. HC/CHR-PS+ vs. CHR-PS-/CHR-PS- vs. HC). We also conducted analyses within a
319 meta-analysis framework and fitted linear mixed models of sMRI data (not adjusted with
320 neuroCombat), with scanner as a random effect. We investigated sMRI differences associated
321 with the specific psychosis-risk syndromes (e.g., Attenuated Positive Symptom Syndrome;
322 details in **Supplement**).

323 To evaluate the stability of group and conversion status differences, we performed
324 analyses statistically controlling for psychotropic medication exposure at baseline. To assess
325 effects of site, we conducted jackknife resampling analyses, i.e., iteratively removing one site's
326 data and re-running respective analyses^{86,87}. sMRI measures that failed to show a group or
327 conversion status effect at q <0.05 in >10% of jackknife iterations (i.e., 4/31 sites) were
328 considered "unstable".

329 To assess the meaningfulness of obtained effect sizes we used two analytic
330 approaches: equivalence testing (to assess whether observed differences fell within the upper
331 and lower bounds of a predefined smallest effect size of interest, providing support for the
332 *absence* of a meaningful effect) and minimal-effects testing (to assess whether observed effects
333 *were greater* than the same pre-defined effect size⁸⁸). Upper/lower bounds (representing the
334 positive/negative predefined smallest effect size of interest) were set to $d = +/- 0.15$ (further
335 details and effect size rationale, see **Supplement**).

336

337 *Group and conversion-related differences in sMRI age-associations*

338 We used general additive models^{89,90} to model group and conversion status differences
339 in the relationship between age and sMRI measures. General additive models extend GLMs by
340 allowing for a non-linear relationship between independent and dependent variables. Here, age
341 is modeled as a smooth function (continuous derivatives), which is akin to the "age-related"
342 slope in a GLM. Analyses were confined to sMRI measures that displayed statistically significant
343 effects of I) HC vs. CHR (N=56 measures) and II) CHR-PS+ vs. HC/CHR-PS+ vs. CHR-PS-
344 /CHR-PS- vs. HC (N=4). We examined the effect of baseline age, group/conversion status, and
345 the interaction between the two variables. Sex and estimated ICV were included as covariates.
346 Similar to prior work examining age effects during adolescent development^{91,92}, we restricted
347 our sample's age range to 12-25 years (**eTable 3**). Details on post-hoc analyses for significant
348 interaction effects are provided in the **Supplement**.

349

350 *Comparison of psychosis conversion-related effects to other ENIGMA findings*

351 We computed Spearman's rank correlations to assess the extent to which the pattern of
352 observed effect sizes (Cohen's d 's for CHR-PS+ vs. HC and CHR-PS-) correlated with the
353 pattern found in prior psychosis studies, specifically the ENIGMA Schizophrenia (SZ vs. HC^{69,70})
354 and ENIGMA 22q11.2 Deletion Syndrome (22q11DS with psychosis vs. 22q11DS without
355 psychosis^{72,73}) Working Groups. As a control, we compared CHR-PS+/CHR-PS- vs. HC effect
356 sizes to effect sizes published by the Major Depressive Disorder Working Group (MDD vs.
357 HC⁹³). Additional details of correlation analyses are reported in the **Supplement**.

358 3. RESULTS

359

360 Sample Characteristics

361 Site demographics are reported in **Table 1**. See **eTables 4-6** for IQ and symptom
362 comparisons. Few CHR participants reported typical (<1%) and/or atypical antipsychotic
363 (12.4%) medication use (**eTable 7**).

364

365 *Widespread lower CT in CHR versus HC*

366 Compared to HC, the CHR group had smaller global neuroimaging measures: estimated
367 ICV ($d=-0.13$, $CI=-0.2$ to -0.06), mean CT ($d=-0.18$, $CI=-0.25$ to -0.11) and total SA ($d=-0.15$,
368 $CI=-0.22$ to -0.08). Fifty-three additional regions exhibited a significant effect of group ($q<0.05$,
369 **eTable 8**). The largest group effects were observed for widespread lower CT in CHR vs. HC
370 (42/68 comparisons, d range= -0.09 to -0.17 ; **Figure 1A** for overview; **eTable 8** and **eFigure 1**
371 for details). Few subcortical (3/16) and SA (8/68) group differences were observed (d range= $-$
372 0.09 to -0.16). No group-by-sex interactions were detected (all $q>0.05$).

373 Group difference magnitudes remained similar when controlling for antipsychotic and
374 psychotropic medication use (**eTable 9**). 91% of group differences remained statistically
375 significant ($q<0.05$) in >90% of jackknife resampling iterations (eFigure 2), providing evidence
376 that site effects were not driving results. Equivalence testing revealed that effect sizes for group
377 differences were likely not meaningfully greater than our *a priori*-defined smallest effect size of
378 interest in 3/56 measures (**eFigure 1**, **eTable 10**).

379 Mega- and meta-analyses of neuroimaging data prior to neuroCombat harmonization
380 provided similar results (Spearman's $\rho>0.93$; **eTable 11**). No sMRI measures were uniquely
381 sensitive to psychosis-risk syndrome (see **Supplement** and **eTables 12-15** for results).

382

383 *Thinner paracentral, fusiform, and superior temporal CT are associated with psychosis* 384 *conversion*

385 Forty-eight structural neuroimaging measures ($N_{CT}=37$) exhibited a significant overall
386 effect of psychosis conversion status ($q<0.05$, **Figure 1B**; **eFigure 3** and **eTable 16**). The three
387 groups differed from each other on four structural neuroimaging measures: in comparison to HC
388 and CHR-PS-, CHR-PS+ exhibited thinner cortex in bilateral paracentral, right superior
389 temporal, and left fusiform regions (**Figure 1C**, average d of four sMRI measures= -0.22). CHR-
390 PS+ and CHR-PS- (vs. HC) exhibited thinner cortex in the left superior temporal and right
391 fusiform regions; similar trends were observed for CHR-PS+ vs. CHR-PS- differences ($p<0.08$;
392 **Figure 1C**). Results remained stable when length of follow-up period was included as a
393 covariate.

394 Using minimal-effects testing, we observed that effect sizes for bilateral paracentral (L
395 $Z=-2.43$, $p=0.02$; R $Z=-1.86$ $p=0.06$), right superior temporal ($Z=-2.29$, $p=0.02$) and left fusiform
396 ($Z=-2.00$, $p=0.05$) in CHR-PS+ vs. HC were all significantly *greater* than 0.15, at least at trend
397 level, underscoring the presence of notable group differences.

398 In the remaining follow-up comparisons, CHR-PS+ and CHR-PS- differed from HC at
399 $p<0.05$, but there were no significant differences between CHR-PS+ and CHR-PS- (29/48
400 comparisons; **eTable 16**). We observed no conversion status-by-sex interactions (all $q>0.05$).

401 When we controlled for antipsychotic or psychotropic medication exposure, most overall
402 psychosis conversion effects remained statistically significant (**eTable 17**). sMRI measures that
403 differentiated the three groups showed an overall conversion effect at $q < 0.05$ in all jackknife
404 iterations, ruling out site effects as a potential confound (**eFigure 2**). No pairwise comparisons
405 for structural neuroimaging measures that showed an overall conversion effect at $q < 0.05$ were
406 statistically equivalent to our predefined smallest effect size of interest (**eTable 18**). There were
407 no statistically significant psychosis-risk syndrome-by-conversion status interactions (**eTable**
408 **19**).

409

410 ***CHR-PS+ fail to show expected age-associations with fusiform and paracentral CT***

411 There were no significant group-by-age interactions in the 56 neuroimaging measures
412 that differed between CHR and HC ($q > 0.05$, **eTable 20**). In contrast, 2/4 sMRI measures in
413 which all groups differed (HC vs. CHR-PS+ vs. CHR-PS-) displayed a statistically significant
414 conversion status-by-age interaction.

415 In left fusiform, age-CT associations differed between CHR-PS+ vs. HC ($F=9.8$, $p=4.9e-$
416 05 , $q=5.9e-04$) and CHR-PS- vs. HC ($F=8.7$, $p=1.5e-04$, $q=9.1e-04$, Figure 2A, left). Between
417 ages 12-16, HC showed a stronger negative association between age and CT, compared to
418 CHR-PS+ and CHR-PS-, suggesting a reduced rate of CT change in CHR-PS+ and CHR-PS-.
419 Though the age-by-conversion status interaction was not statistically significant, a similar
420 pattern emerged for the right fusiform CT (Figure 2A, right).

421 Age-effects in the left paracentral CT differed between CHR-PS+ vs. HC ($F=5.9$, $p=4.9e-$
422 03 , $q=0.02$, Figure 2B, left). Between 12-15.8 years of age, HC showed a stronger negative
423 association between age and CT in comparison to CHR-PS+. Age-CT associations did not differ
424 between CHR-PS- vs. HC ($F=0.2$, $p=0.69$). This pattern of results was not observed for the right
425 paracentral CT (Figure 2B, right).

426 We found no significant age-by-conversion status interactions for the superior temporal
427 CT (Figure 2C); all three groups showed negative CT-age associations.

428

429 ***CT aberrations in CHR-PS+ resemble the pattern observed in SZ and 22q11DS with a*** 430 ***psychotic disorder diagnosis, but not MDD***

431 **Figure 3A** provides a visual overview of CT alterations in CHR-PS+ relative to SZ and
432 individuals with 22q11DS and a psychotic disorder. The pattern of baseline CT alterations in
433 CHR-PS+ (CHR-PS+ vs. HC effect sizes) correlated significantly with that observed in SZ
434 ($\rho=0.35$, $p_{\text{permute}}=0.004$, **Figure 3B** top) and individuals with 22q11DS and psychosis ($\rho=0.43$,
435 $p_{\text{permute}}=0.001$, **Figure 3B** bottom). CT alterations in CHR did *not* correlate with those observed
436 in MDD (CHR-PS+ $\rho=-0.03$) and slopes for CHR-PS+/SZ and CHR-PS+/MDD correlations
437 significantly differed (Steiger's $Z=2.06$, $p_{\text{permute}}=0.008$). No significant correlations were observed
438 for SA (SZ $\rho=-0.03$; 22q.11DS $\rho=-0.06$, eFigure 5). Subcortical volume alterations in CHR-PS+
439 correlated with those observed in SZ ($\rho=0.54$, $p=0.03$) and a similar non-significant trend was
440 observed for 22q11DS and psychosis ($\rho=0.46$, $p=0.07$). Associations for CHR-PS- (vs. HC)
441 effect sizes were similar to those reported here (see **Supplement**).

442

443 4. DISCUSSION

444

445 We conducted the largest multisite neuroimaging investigation to date in CHR
446 participants, examining baseline structural neuroimaging measures associated with later
447 transition to psychosis. We found widespread thinner cortex in CHR, consistent with previously-
448 reported CT alterations in individuals with an established psychotic disorder. Compared to CHR-
449 PS- and HC, at baseline, CHR-PS+ exhibited thinner cortex in bilateral paracentral, right
450 fusiform and left superior temporal regions, with effect sizes significantly greater than what we
451 considered to be meaningful *a priori*. Our results were robust to effects of medication exposure,
452 sex, site, and length of follow-up period. Findings from this international effort suggest that
453 conversion to psychosis amongst those at high risk is associated with thinner cortex at baseline.

454 We identified widespread regional thinner cortex in CHR compared to HC. Thinner
455 cortex has been observed in SZ, as well as other psychiatric disorders^{69,79,93–95}. Importantly, the
456 overall pattern of thinner cortex in CHR resembled that observed in SZ and individuals with
457 22q11DS and a psychotic disorder, but not in MDD. For CHR-PS+, correlations with SZ CT
458 alterations were significantly greater than the relationship observed with MDD CT alterations.
459 Taken together, our results suggest that the overall constellation of reported CT alterations
460 resembles the regional pattern of alterations observed in SZ and genetic disorders associated
461 with psychosis, and thus argues in favour of psychosis-specific thinner cortex in CHR

462 We also observed thinner cortex specific to psychosis conversion in paracentral,
463 superior temporal and fusiform CT; CHR-PS+ exhibit significantly lower CT than CHR-PS- and
464 HC in these regions. Lower baseline CT and/or volume in these regions has previously been
465 reported in CHR-PS+^{96,97} (data not used here). Furthermore, longitudinal CT decreases in these
466 regions have been associated with transition to psychosis in CHR^{17,98,99}. The magnitude of
467 altered CT in CHR-PS+ in paracentral, superior temporal and fusiform regions was highly
468 consistent with findings in SZ^{70,100–102} and lower fusiform and paracentral CT has been observed
469 in non-clinical voice hearers¹⁰³. Thus, the observed pattern of CT alterations in CHR-PS+ is
470 consistent with morphometric disruptions across the wider psychosis spectrum.

471 Consistent with previous CHR studies examining baseline neuroimaging associations
472 with later conversion to psychosis^{96,104}, we did not observe widespread subcortical volume or SA
473 alterations associated with later psychosis transition. Taken together, these results suggest that
474 CT reductions may be among the most widespread, robust, and specific morphometric changes
475 associated with psychosis risk and conversion, compared to SA or subcortical volume.

476 The neuroanatomic pattern of group differences and age-associated disruptions
477 observed in CHR may provide important insights into mechanisms underlying increased risk for
478 psychosis. Pre-clinical models^{105,106} and recent genome-wide association studies¹⁰⁷ suggest
479 that genetic variants associated with SZ are linked to the regulation of neural progenitor cells
480 during fetal development, while genetic markers associated with CT were associated with
481 regulatory processes in adulthood. Thus, CT alterations may be the end result of maladaptive
482 maturation-related mechanisms that occur during post-fetal development, including proliferation,
483 synaptic pruning and/or myelination^{108–111}. Thinner CT, particularly in early adolescence^{112,113}
484 (**Figure 2**), could reflect abnormal synaptic plasticity or pruning, which have both been
485 implicated in *in vitro* SZ models¹¹⁴. Although excessive synaptic pruning is one plausible
486 explanation for thinner cortex associated with psychosis transition, recent evidence suggests

487 that intracortical myelination and/or expression of myelin-related genes may be mechanisms
488 driving cortical thinning^{115,116}. To better understand neurobiological mechanisms underlying
489 psychosis transition in CHR, investigations of concomitant measures of cortical thickness,
490 macroscale white matter tracts, and intracortical myelination are necessary.

491 Even if CT reductions in CHR were robust, effect sizes for between-group differences
492 were nevertheless small-to-moderate and accounted for ~1% of the variance in CHR-PS+ vs.
493 CHR-PS- comparisons. The subtle nature of these morphometric alterations underscores the
494 importance of adequate statistical power, achievable only through large-scale multi-site
495 collaborations. Consistent with recent work showing that SZ polygenic risk scores only improved
496 differentiation of CHR-PS+ and HC (not CHR-PS+ from CHR-PS-)¹¹⁷, we anticipate that
497 baseline, univariate sMRI metrics will to have a similar impact on psychosis risk prediction
498 algorithms. Given the logistic and financial challenges that MRI brings, the use of MRI metrics in
499 isolation may not be feasible or useful for psychosis risk prediction. A viable solution may be to
500 adopt sequential assessment frameworks, as recently implemented³⁴. Alternatively, sMRI
501 alterations may be a better predictor of general psychopathology, and would be better suited for
502 transdiagnostic risk prediction models^{118,119}.

503

504 **Limitations**

505 One limitation common to multi-site studies is that data were collected from multiple
506 scanners, although leave-one-out analyses suggest that site effects were not prominent.
507 Secondly, this initial study focused on baseline cross-sectional data, and did not investigate
508 progressive sMRI changes (trajectories) associated with psychosis conversion, as identified in
509 prior work^{17,19,38,97–99,120–123}. This is a future goal of the ENIGMA CHR Working Group, now that
510 feasibility of this collaboration has been established.

511

512 **Conclusions and Future Directions**

513 In the largest study of brain abnormalities in CHR to date, we found robust evidence for a
514 subtle, widespread pattern of CT alterations, consistent with observations in psychosis. The
515 specificity of these alterations to CT - as well as age-associated deviations in regions sensitive
516 to psychosis conversion - may point to abnormal development processes. These findings also
517 point to age ranges (i.e., early adolescence) when morphometric abnormalities in CHR might be
518 greatest.

519

520 **Acknowledgements**

521 BHE (Bjørn H. Ebdrup) is part of the Advisory Board of Eli Lilly Denmark A/S, Janssen-
522 Cilag, Lundbeck Pharma A/S, and Takeda Pharmaceutical Company Ltd; and has
523 received lecture fees from Bristol-Myers Squibb, Otsuka Pharma Scandinavia AB, Eli
524 Lilly Company, Boehringer Ingelheim Danmark A/S, and Lundbeck Pharma A/S. DH
525 (Dennis Hernaus) has received financial compensation as a consultant for P1vital
526 Products Ltd. F-RM (Francisco Reyes-Madrigal) has received compensation as a
527 speaker for Janssen (Johnson & Johnson). All reported activities were unrelated to the
528 work presented in this manuscript.

529

530 References

- 531
- 532 1. Miller TJ, McGlashan TH, Rosen JL, et al. Prodromal assessment with the structured
533 interview for prodromal syndromes and the scale of prodromal symptoms: predictive
534 validity, interrater reliability, and training to reliability. *Schizophr Bull.* 2003;29(4):703.
- 535 2. Yung AR, McGorry PD, McFarlane CA, Jackson HJ, Patton GC, Rakkar A. Monitoring
536 and care of young people at incipient risk of psychosis. *Schizophr Bull.* 1996;22(2):283-
537 303. doi:10.1093/schbul/22.2.283
- 538 3. Yung AR, Phillips LJ, McGorry PD, et al. Prediction of psychosis. A step towards
539 indicated prevention of schizophrenia. *Br J Psychiatry Suppl.* 1998;172(33):14-20.
- 540 4. Fusar-Poli P, Bonoldi I, Yung AR, et al. Predicting psychosis: meta-analysis of transition
541 outcomes in individuals at high clinical risk. *Arch Gen Psychiatry.* 2012;69(3):220-229.
542 doi:10.1001/archgenpsychiatry.2011.1472
- 543 5. Simon AE, Umbricht D. High remission rates from an initial ultra-high risk state for
544 psychosis. *Schizophr Res.* 2010;116(2-3):168-172. doi:10.1016/j.schres.2009.10.001
- 545 6. Ruhrmann S, Schultze-Lutter F, Salokangas RKR, et al. Prediction of psychosis in
546 adolescents and young adults at high risk: results from the prospective European
547 prediction of psychosis study. *Arch Gen Psychiatry.* 2010;67(3):241-251.
548 doi:10.1001/archgenpsychiatry.2009.206
- 549 7. Cannon TD, Cadenhead K, Cornblatt B, et al. Prediction of Psychosis in Youth at High
550 Clinical Risk: A Multisite Longitudinal Study in North America. *Arch Gen Psychiatry.*
551 2008;65(1):28. doi:10.1001/archgenpsychiatry.2007.3
- 552 8. Yung AR, Phillips LJ, Yuen HP, et al. Psychosis prediction: 12-month follow up of a high-
553 risk ("prodromal") group. *Schizophr Res.* 2003;60(1):21-32. doi:10.1016/s0920-
554 9964(02)00167-6
- 555 9. Cornblatt BA, Lencz T, Smith CW, Correll CU, Auther AM, Nakayama E. The
556 schizophrenia prodrome revisited: a neurodevelopmental perspective. *Schizophr Bull.*
557 2003;29(4):633-651. doi:10.1093/oxfordjournals.schbul.a007036
- 558 10. Zhang T, Li H, Tang Y, et al. Validating the Predictive Accuracy of the NAPLS-2
559 Psychosis Risk Calculator in a Clinical High-Risk Sample from the SHARP (Shanghai At
560 Risk for Psychosis) Program. *Am J Psychiatry.* 2018;175(9):906-908.
561 doi:10.1176/appi.ajp.2018.18010036
- 562 11. Tor J, Dolz M, Sintes A, et al. Clinical high risk for psychosis in children and adolescents:
563 a systematic review. *Eur Child Adolesc Psychiatry.* 2018;27(6):683-700.
564 doi:10.1007/s00787-017-1046-3
- 565 12. Hartmann JA, Yuen HP, McGorry PD, et al. Declining transition rates to psychotic
566 disorder in "ultra-high risk" clients: Investigation of a dilution effect. *Schizophr Res.*
567 2016;170(1):130-136. doi:10.1016/j.schres.2015.11.026
- 568 13. Fusar-Poli P, Palombini E, Davies C, et al. Why transition risk to psychosis is not
569 declining at the OASIS ultra high risk service: The hidden role of stable pretest risk
570 enrichment. *Schizophr Res.* 2018;192:385-390. doi:10.1016/j.schres.2017.06.015
- 571 14. Bakker G, Caan MWA, Vingerhoets WAM, et al. Cortical Morphology Differences in
572 Subjects at Increased Vulnerability for Developing a Psychotic Disorder: A Comparison
573 between Subjects with Ultra-High Risk and 22q11.2 Deletion Syndrome. *PLOS ONE.*
574 2016;11(11):e0159928. doi:10.1371/journal.pone.0159928
- 575 15. Zikidi K, Gajwani R, Gross J, et al. Grey-matter abnormalities in clinical high-risk
576 participants for psychosis. *Schizophr Res.* Published online November 15, 2019.
577 doi:10.1016/j.schres.2019.08.034
- 578 16. Velakoulis D, Wood SJ, Wong MTH, et al. Hippocampal and Amygdala Volumes
579 According to Psychosis Stage and Diagnosis: A Magnetic Resonance Imaging Study of
580 Chronic Schizophrenia, First-Episode Psychosis, and Ultra-High-Risk Individuals. *Arch*

- 581 *Gen Psychiatry*. 2006;63(2):139. doi:10.1001/archpsyc.63.2.139
- 582 17. Sun D, Phillips L, Velakoulis D, et al. Progressive brain structural changes mapped as
583 psychosis develops in 'at risk' individuals. *Schizophrenia Research*. 2009;108(1-3):85-92.
584 doi:10.1016/j.schres.2008.11.026
- 585 18. Fornito A, Yung AR, Wood SJ, et al. Anatomic Abnormalities of the Anterior Cingulate
586 Cortex Before Psychosis Onset: An MRI Study of Ultra-High-Risk Individuals. *Biological*
587 *Psychiatry*. 2008;64(9):758-765. doi:10.1016/j.biopsych.2008.05.032
- 588 19. Takahashi T, Wood SJ, Yung AR, et al. Insular cortex gray matter changes in individuals
589 at ultra-high-risk of developing psychosis. *Schizophrenia Research*. 2009;111(1-3):94-
590 102. doi:10.1016/j.schres.2009.03.024
- 591 20. Tomyshev AS, Lebedeva IS, Akhadov TA, Omelchenko MA, Rummyantsev AO, Kaleda
592 VG. Alterations in white matter microstructure and cortical thickness in individuals at ultra-
593 high risk of psychosis: A multimodal tractography and surface-based morphometry study.
594 *Psychiatry Res Neuroimaging*. 2019;289:26-36. doi:10.1016/j.pscychresns.2019.05.002
- 595 21. Kwak YB, Kim M, Cho KIK, Lee J, Lee TY, Kwon JS. Reduced cortical thickness in
596 subjects at clinical high risk for psychosis and clinical attributes. *Aust N Z J Psychiatry*.
597 2019;53(3):219-227. doi:10.1177/0004867418807299
- 598 22. Yassin W, Nakatani H, Zhu Y, et al. Machine-learning classification using neuroimaging
599 data in schizophrenia, autism, ultra-high risk and first-episode psychosis. *Transl*
600 *Psychiatry*. 2020;10(1):278. doi:10.1038/s41398-020-00965-5
- 601 23. Nakamura M, Takahashi T, Takayanagi Y, et al. Surface morphology of the orbitofrontal
602 cortex in individuals at risk of psychosis: a multicenter study. *Eur Arch Psychiatry Clin*
603 *Neurosci*. 2019;269(4):397-406. doi:10.1007/s00406-018-0890-6
- 604 24. Sasabayashi D, Takayanagi Y, Takahashi T, et al. Increased Occipital Gyrfication and
605 Development of Psychotic Disorders in Individuals With an At-Risk Mental State:
606 A Multicenter Study. *Biol Psychiatry*. 2017;82(10):737-745.
607 doi:10.1016/j.biopsych.2017.05.018
- 608 25. Iwashiro N, Suga M, Takano Y, et al. Localized gray matter volume reductions in the pars
609 triangularis of the inferior frontal gyrus in individuals at clinical high-risk for psychosis and
610 first episode for schizophrenia. *Schizophr Res*. 2012;137(1-3):124-131.
611 doi:10.1016/j.schres.2012.02.024
- 612 26. Nakamura K, Takahashi T, Nemoto K, et al. Gray matter changes in subjects at high risk
613 for developing psychosis and first-episode schizophrenia: a voxel-based structural MRI
614 study. *Front Psychiatry*. 2013;4:16. doi:10.3389/fpsyt.2013.00016
- 615 27. Takayanagi Y, Kulason S, Sasabayashi D, et al. Reduced Thickness of the Anterior
616 Cingulate Cortex in Individuals With an At-Risk Mental State Who Later Develop
617 Psychosis. *Schizophr Bull*. 2017;43(4):907-913. doi:10.1093/schbul/sbw167
- 618 28. Takahashi T, Tsugawa S, Nakajima S, et al. Thalamic and striato-pallidal volumes in
619 schizophrenia patients and individuals at risk for psychosis: A multi-atlas segmentation
620 study. *Schizophr Res*. Published online May 21, 2020. doi:10.1016/j.schres.2020.04.016
- 621 29. Buechler R, Wotruba D, Michels L, et al. Cortical Volume Differences in Subjects at Risk
622 for Psychosis are Driven by Surface Area. *Schizophr Bull*. Published online May 28,
623 2020. doi:10.1093/schbul/sbaa066
- 624 30. Chung Y, Allswede D, Addington J, et al. Cortical abnormalities in youth at clinical high-
625 risk for psychosis: Findings from the NAPLS2 cohort. *Neuroimage Clin*. 2019;23:101862.
626 doi:10.1016/j.nicl.2019.101862
- 627 31. Chung Y, Addington J, Bearden CE, et al. Use of Machine Learning to Determine
628 Deviance in Neuroanatomical Maturity Associated With Future Psychosis in Youths at
629 Clinically High Risk. *JAMA Psychiatry*. 2018;75(9):960-968.
630 doi:10.1001/jamapsychiatry.2018.1543
- 631 32. Koutsouleris N, Meisenzahl EM, Davatzikos C, et al. Use of neuroanatomical pattern

- 632 classification to identify subjects in at-risk mental states of psychosis and predict disease
633 transition. *Arch Gen Psychiatry*. 2009;66(7):700-712.
634 doi:10.1001/archgenpsychiatry.2009.62
- 635 33. Koutsouleris N, Riecher-Rössler A, Meisenzahl EM, et al. Detecting the psychosis
636 prodrome across high-risk populations using neuroanatomical biomarkers. *Schizophr*
637 *Bull*. 2015;41(2):471-482. doi:10.1093/schbul/sbu078
- 638 34. Koutsouleris N, Kambaitz-Illankovic L, Ruhrmann S, et al. Prediction Models of Functional
639 Outcomes for Individuals in the Clinical High-Risk State for Psychosis or With Recent-
640 Onset Depression: A Multimodal, Multisite Machine Learning Analysis. *JAMA Psychiatry*.
641 2018;75(11):1156-1172. doi:10.1001/jamapsychiatry.2018.2165
- 642 35. Klauser P, Zhou J, Lim JKW, et al. Lack of Evidence for Regional Brain Volume or
643 Cortical Thickness Abnormalities in Youths at Clinical High Risk for Psychosis: Findings
644 From the Longitudinal Youth at Risk Study. *Schizophr Bull*. 2015;41(6):1285-1293.
645 doi:10.1093/schbul/sbv012
- 646 36. Ziermans TB, Durston S, Sprong M, et al. No evidence for structural brain changes in
647 young adolescents at ultra high risk for psychosis. *Schizophr Res*. 2009;112(1-3):1-6.
648 doi:10.1016/j.schres.2009.04.013
- 649 37. Takahashi T, Yücel M, Yung AR, et al. Adhesio interthalamica in individuals at high-risk
650 for developing psychosis and patients with psychotic disorders. *Prog*
651 *Neuropsychopharmacol Biol Psychiatry*. 2008;32(7):1708-1714.
652 doi:10.1016/j.pnpbp.2008.07.007
- 653 38. Cannon TD, Chung Y, He G, et al. Progressive reduction in cortical thickness as
654 psychosis develops: a multisite longitudinal neuroimaging study of youth at elevated
655 clinical risk. *Biol Psychiatry*. 2015;77(2):147-157. doi:10.1016/j.biopsych.2014.05.023
- 656 39. Sakuma A, Obara C, Katsura M, et al. No regional gray matter volume reduction
657 observed in young Japanese people at ultra-high risk for psychosis: A voxel-based
658 morphometry study. *Asian J Psychiatr*. 2018;37:167-171. doi:10.1016/j.ajp.2018.09.009
- 659 40. Fusar-Poli P, Borgwardt S, Crescini A, et al. Neuroanatomy of vulnerability to psychosis:
660 a voxel-based meta-analysis. *Neurosci Biobehav Rev*. 2011;35(5):1175-1185.
661 doi:10.1016/j.neubiorev.2010.12.005
- 662 41. Mechelli A, Riecher-Rössler A, Meisenzahl EM, et al. Neuroanatomical abnormalities that
663 predate the onset of psychosis: a multicenter study. *Arch Gen Psychiatry*.
664 2011;68(5):489-495. doi:10.1001/archgenpsychiatry.2011.42
- 665 42. Farris MS, Devoe DJ, Addington J. Attrition rates in trials for adolescents and young
666 adults at clinical high-risk for psychosis: A systematic review and meta-analysis. *Early*
667 *Interv Psychiatry*. 2020;14(5):515-527. doi:10.1111/eip.12864
- 668 43. Schlosser DA, Jacobson S, Chen Q, et al. Recovery from an at-risk state: clinical and
669 functional outcomes of putatively prodromal youth who do not develop psychosis.
670 *Schizophr Bull*. 2012;38(6):1225-1233. doi:10.1093/schbul/sbr098
- 671 44. Rutigliano G, Valmaggia L, Landi P, et al. Persistence or recurrence of non-psychotic
672 comorbid mental disorders associated with 6-year poor functional outcomes in patients at
673 ultra high risk for psychosis. *J Affect Disord*. 2016;203:101-110.
674 doi:10.1016/j.jad.2016.05.053
- 675 45. Simon AE, Borgwardt S, Riecher-Rössler A, Velthorst E, de Haan L, Fusar-Poli P. Moving
676 beyond transition outcomes: meta-analysis of remission rates in individuals at high clinical
677 risk for psychosis. *Psychiatry Res*. 2013;209(3):266-272.
678 doi:10.1016/j.psychres.2013.03.004
- 679 46. Button KS, Ioannidis JPA, Mokrysz C, et al. Power failure: why small sample size
680 undermines the reliability of neuroscience. *Nat Rev Neurosci*. 2013;14(5):365-376.
681 doi:10.1038/nrn3475
- 682 47. Consideration of Sample Size in Neuroscience Studies. *J Neurosci*. 2020;40(21):4076-

- 683 4077. doi:10.1523/JNEUROSCI.0866-20.2020
- 684 48. Addington J, Cadenhead KS, Cornblatt BA, et al. North American Prodrome Longitudinal
685 Study (NAPLS 2): Overview and recruitment. *Schizophrenia Research*. 2012;142(1):77-
686 82. doi:10.1016/j.schres.2012.09.012
- 687 49. Addington J, Liu L, Brummitt K, et al. North American Prodrome Longitudinal Study
688 (NAPLS 3): Methods and baseline description. *Schizophrenia Research*. Published online
689 April 18, 2020. doi:10.1016/j.schres.2020.04.010
- 690 50. Tognin S, van Hell HH, Merritt K, et al. Towards Precision Medicine in Psychosis:
691 Benefits and Challenges of Multimodal Multicenter Studies-PSYSCAN: Translating
692 Neuroimaging Findings From Research into Clinical Practice. *Schizophr Bull*.
693 2020;46(2):432-441. doi:10.1093/schbul/sbz067
- 694 51. Jones P, Rodgers B, Murray R, Marmot M. Child development risk factors for adult
695 schizophrenia in the British 1946 birth cohort. *Lancet*. 1994;344(8934):1398-1402.
696 doi:10.1016/s0140-6736(94)90569-x
- 697 52. Lauronen E, Miettunen J, Veijola J, Karhu M, Jones PB, Isohanni M. Outcome and its
698 predictors in schizophrenia within the Northern Finland 1966 Birth Cohort. *Eur Psychiatry*.
699 2007;22(2):129-136. doi:10.1016/j.eurpsy.2006.07.001
- 700 53. Giedd JN, Blumenthal J, Jeffries NO, et al. Brain development during childhood and
701 adolescence: a longitudinal MRI study. *Nature Neuroscience*. 1999;2(10):861-863.
702 doi:10.1038/13158
- 703 54. Raznahan A, Shaw P, Lalonde F, et al. How Does Your Cortex Grow? *Journal of*
704 *Neuroscience*. 2011;31(19):7174–7177.
- 705 55. Sowell ER. Longitudinal Mapping of Cortical Thickness and Brain Growth in Normal
706 Children. *Journal of Neuroscience*. 2004;24(38):8223–8231.
- 707 56. Shaw P, Lerch J, Greenstein D, et al. Longitudinal mapping of cortical thickness and
708 clinical outcome in children and adolescents with attention-deficit/hyperactivity disorder.
709 *Arch Gen Psychiatry*. 2006;63(5):540-549. doi:10.1001/archpsyc.63.5.540
- 710 57. van Soelen ILC, Brouwer RM, van Baal GCM, et al. Genetic influences on thinning of the
711 cerebral cortex during development. *Neuroimage*. 2012;59(4):3871-3880.
712 doi:10.1016/j.neuroimage.2011.11.044
- 713 58. Vijayakumar N, Allen NB, Youssef G, et al. Brain development during adolescence: A
714 mixed-longitudinal investigation of cortical thickness, surface area, and volume. *Hum*
715 *Brain Mapp*. 2016;37(6):2027-2038. doi:10.1002/hbm.23154
- 716 59. Tamnes CK, Herting MM, Goddings A-L, et al. Development of the Cerebral Cortex
717 across Adolescence: A Multisample Study of Inter-Related Longitudinal Changes in
718 Cortical Volume, Surface Area, and Thickness. *J Neurosci*. 2017;37(12):3402-3412.
719 doi:10.1523/JNEUROSCI.3302-16.2017
- 720 60. Mills KL, Goddings A-L, Herting MM, et al. Structural brain development between
721 childhood and adulthood: Convergence across four longitudinal samples. *Neuroimage*.
722 2016;141:273–281.
- 723 61. Mills KL, Goddings A-L, Clasen LS, Giedd JN, Blakemore S-J. The developmental
724 mismatch in structural brain maturation during adolescence. *Dev Neurosci*. 2014;36(3-
725 4):147-160. doi:10.1159/000362328
- 726 62. Mills KL, Tamnes CK. Methods and considerations for longitudinal structural brain
727 imaging analysis across development. *Dev Cogn Neurosci*. 2014;9:172-190.
728 doi:10.1016/j.dcn.2014.04.004
- 729 63. Mills KL, Lalonde F, Clasen LS, Giedd JN, Blakemore S-J. Developmental changes in the
730 structure of the social brain in late childhood and adolescence. *Soc Cogn Affect Neurosci*.
731 2014;9(1):123-131. doi:10.1093/scan/nss113
- 732 64. Bridgwater M, Bachman P, Tervo-Clemmens B, et al. Developmental influences on
733 symptom expression in antipsychotic-naïve first-episode psychosis. *Psychol Med*.

- 734 Published online October 6, 2020:1-12. doi:10.1017/S0033291720003463
- 735 65. Schimmelmann BG, Michel C, Martz-Irngartinger A, Linder C, Schultze-Lutter F. Age
736 matters in the prevalence and clinical significance of ultra-high-risk for psychosis
737 symptoms and criteria in the general population: Findings from the BEAR and BEARS-kid
738 studies. *World Psychiatry*. 2015;14(2):189–197.
- 739 66. Gerstenberg M, Theodoridou A, Traber-Walker N, et al. Adolescents and adults at clinical
740 high-risk for psychosis: age-related differences in attenuated positive symptoms
741 syndrome prevalence and entanglement with basic symptoms. *Psychol Med*.
742 2016;46(5):1069-1078. doi:10.1017/S0033291715002627
- 743 67. Schultze-Lutter F, Hubl D, Schimmelmann BG, Michel C. Age effect on prevalence of
744 ultra-high risk for psychosis symptoms: replication in a clinical sample of an early
745 detection of psychosis service. *Eur Child Adolesc Psychiatry*. 2017;26(11):1401-1405.
746 doi:10.1007/s00787-017-0994-y
- 747 68. Schultze-Lutter F, Schimmelmann BG, Flückiger R, Michel C. Effects of age and sex on
748 clinical high-risk for psychosis in the community. *World J Psychiatry*. 2020;10(5):101-124.
749 doi:10.5498/wjp.v10.i5.101
- 750 69. van Erp TGM, Hibar DP, Rasmussen JM, et al. Subcortical brain volume abnormalities in
751 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA
752 consortium. *Molecular Psychiatry*. 2016;21(4):547-553. doi:10.1038/mp.2015.63
- 753 70. van Erp TGM, Walton E, Hibar DP, et al. Cortical Brain Abnormalities in 4474 Individuals
754 With Schizophrenia and 5098 Control Subjects via the Enhancing Neuro Imaging
755 Genetics Through Meta Analysis (ENIGMA) Consortium. *Biol Psychiatry*. 2018;84(9):644-
756 654. doi:10.1016/j.biopsych.2018.04.023
- 757 71. Okada N, Fukunaga M, Yamashita F, et al. Abnormal asymmetries in subcortical brain
758 volume in schizophrenia. *Mol Psychiatry*. 2016;21(10):1460-1466.
759 doi:10.1038/mp.2015.209
- 760 72. Ching CRK, Gutman BA, Sun D, et al. Mapping Subcortical Brain Alterations in 22q11.2
761 Deletion Syndrome: Effects of Deletion Size and Convergence With Idiopathic
762 Neuropsychiatric Illness. *AJP*. Published online February 12, 2020:appi.ajp.2019.1.
763 doi:10.1176/appi.ajp.2019.19060583
- 764 73. Sun D, Ching CRK, Lin A, et al. Large-scale mapping of cortical alterations in 22q11.2
765 deletion syndrome: Convergence with idiopathic psychosis and effects of deletion size.
766 *Mol Psychiatry*. Published online June 13, 2018. doi:10.1038/s41380-018-0078-5
- 767 74. World Medical Association. World Medical Association Declaration of Helsinki: ethical
768 principles for medical research involving human subjects. *JAMA*. 2013;310(20):2191-
769 2194. doi:10.1001/jama.2013.281053
- 770 75. Dale AM, Fischl B, Sereno MI. Cortical surface-based analysis. I. Segmentation and
771 surface reconstruction. *Neuroimage*. 1999;9(2):179–194.
- 772 76. Fischl B, Sereno MI, Dale AM. Cortical surface-based analysis. II: Inflation, flattening, and
773 a surface-based coordinate system. *Neuroimage*. 1999;9(2):195–207.
- 774 77. Fischl B, Dale AM. Measuring the thickness of the human cerebral cortex from magnetic
775 resonance images. *Proc Natl Acad Sci U S A*. 2000;97(20):11050-11055.
776 doi:10.1073/pnas.200033797
- 777 78. Fischl B, Salat DH, Busa E, et al. Whole brain segmentation: automated labeling of
778 neuroanatomical structures in the human brain. *Neuron*. 2002;33(3):341–355.
- 779 79. Hibar DP, Westlye LT, Doan NT, et al. Cortical abnormalities in bipolar disorder: an MRI
780 analysis of 6503 individuals from the ENIGMA Bipolar Disorder Working Group. *Mol*
781 *Psychiatry*. 2018;23(4):932-942. doi:10.1038/mp.2017.73
- 782 80. van Rooij D, Anagnostou E, Arango C, et al. Cortical and Subcortical Brain Morphometry
783 Differences Between Patients With Autism Spectrum Disorder and Healthy Individuals
784 Across the Lifespan: Results From the ENIGMA ASD Working Group. *Am J Psychiatry*.

- 785 2018;175(4):359-369. doi:10.1176/appi.ajp.2017.17010100
- 786 81. Hoogman M, Bralten J, Hibar DP, et al. Subcortical brain volume differences in
787 participants with attention deficit hyperactivity disorder in children and adults: a cross-
788 sectional mega-analysis. *Lancet Psychiatry*. 2017;4(4):310–319.
- 789 82. Boedhoe PSW, Schmaal L, Abe Y, et al. Cortical Abnormalities Associated With Pediatric
790 and Adult Obsessive-Compulsive Disorder: Findings From the ENIGMA Obsessive-
791 Compulsive Disorder Working Group. *Am J Psychiatry*. 2018;175(5):453-462.
792 doi:10.1176/appi.ajp.2017.17050485
- 793 83. Radua J, Vieta E, Shinohara R, et al. Increased power by harmonizing structural MRI site
794 differences with the ComBat batch adjustment method in ENIGMA. *Neuroimage*.
795 2020;218:116956. doi:10.1016/j.neuroimage.2020.116956
- 796 84. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data
797 using empirical Bayes methods. *Biostatistics*. 2007;8(1):118-127.
798 doi:10.1093/biostatistics/kxj037
- 799 85. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful
800 Approach to Multiple Testing. *Journal of the Royal Statistical Society: Series B*
801 *(Methodological)*. 1995;57(1):289-300. doi:https://doi.org/10.1111/j.2517-
802 6161.1995.tb02031.x
- 803 86. Efron B, Stein C. The Jackknife Estimate of Variance. *Ann Statist*. 1981;9(3):586-596.
804 doi:10.1214/aos/1176345462
- 805 87. Efron B. *The Jackknife, the Bootstrap, and Other Resampling Plans*. Society for Industrial
806 and Applied Mathematics (SIAM, 3600 Market Street, Floor 6, Philadelphia, PA 19104);
807 1982.
- 808 88. Lakens D. Equivalence Tests: A Practical Primer for t Tests, Correlations, and Meta-
809 Analyses. *Soc Psychol Personal Sci*. 2017;8(4):355-362.
810 doi:10.1177/1948550617697177
- 811 89. Hastie T, Tibshirani R. Generalized Additive Models. *Statist Sci*. 1986;1(3):297-310.
812 doi:10.1214/ss/1177013604
- 813 90. Hastie T, Tibshirani R. *Generalized Additive Models*. CRC Press; 1990.
- 814 91. Jalbrzikowski M, Larsen B, Hallquist MN, Foran W, Calabro F, Luna B. Development of
815 White Matter Microstructure and Intrinsic Functional Connectivity Between the Amygdala
816 and Ventromedial Prefrontal Cortex: Associations With Anxiety and Depression. *Biol*
817 *Psychiatry*. 2017;82(7):511-521. doi:10.1016/j.biopsych.2017.01.008
- 818 92. Marek S, Hwang K, Foran W, Hallquist MN, Luna B. The Contribution of Network
819 Organization and Integration to the Development of Cognitive Control. *PLoS Biol*.
820 2015;13(12):e1002328. doi:10.1371/journal.pbio.1002328
- 821 93. Schmaal L, Veltman DJ, van Erp TGM, et al. Subcortical brain alterations in major
822 depressive disorder: findings from the ENIGMA Major Depressive Disorder working
823 group. *Mol Psychiatry*. 2016;21(6):806-812. doi:10.1038/mp.2015.69
- 824 94. Rimol LM, Nesvåg R, Hagler DJ, et al. Cortical volume, surface area, and thickness in
825 schizophrenia and bipolar disorder. *Biol Psychiatry*. 2012;71(6):552-560.
826 doi:10.1016/j.biopsych.2011.11.026
- 827 95. Writing Committee for the Attention-Deficit/Hyperactivity Disorder, Autism Spectrum
828 Disorder, Bipolar Disorder, et al. Virtual Histology of Cortical Thickness and Shared
829 Neurobiology in 6 Psychiatric Disorders. *JAMA Psychiatry*. Published online August 26,
830 2020. doi:10.1001/jamapsychiatry.2020.2694
- 831 96. Del Re EC, Stone WS, Bouix S, et al. Baseline Cortical Thickness Reductions in Clinical
832 High Risk for Psychosis: Brain Regions Associated with Conversion to Psychosis Versus
833 Non-Conversion as Assessed at One-Year Follow-Up in the Shanghai-At-Risk-for-
834 Psychosis (SHARP) Study. *Schizophr Bull*. Published online September 14, 2020.
835 doi:10.1093/schbul/sbaa127

- 836 97. Borgwardt SJ, McGuire PK, Aston J, et al. Structural brain abnormalities in individuals
837 with an at-risk mental state who later develop psychosis. *Br J Psychiatry Suppl.*
838 2007;51:s69-75. doi:10.1192/bjp.191.51.s69
- 839 98. Pantelis C, Velakoulis D, McGorry PD, et al. Neuroanatomical abnormalities before and
840 after onset of psychosis: a cross-sectional and longitudinal MRI comparison. *Lancet.*
841 2003;361(9354):281–288.
- 842 99. Takahashi T, Wood SJ, Yung AR, et al. Progressive gray matter reduction of the superior
843 temporal gyrus during transition to psychosis. *Arch Gen Psychiatry.* 2009;66(4):366-376.
844 doi:10.1001/archgenpsychiatry.2009.12
- 845 100. Lee CU, Shenton ME, Salisbury DF, et al. Fusiform gyrus volume reduction in first-
846 episode schizophrenia: a magnetic resonance imaging study. *Arch Gen Psychiatry.*
847 2002;59(9):775-781. doi:10.1001/archpsyc.59.9.775
- 848 101. Onitsuka T, Shenton ME, Kasai K, et al. Fusiform gyrus volume reduction and facial
849 recognition in chronic schizophrenia. *Arch Gen Psychiatry.* 2003;60(4):349-355.
850 doi:10.1001/archpsyc.60.4.349
- 851 102. Takahashi T, Suzuki M, Zhou S-Y, et al. Temporal lobe gray matter in schizophrenia
852 spectrum: a volumetric MRI study of the fusiform gyrus, parahippocampal gyrus, and
853 middle and inferior temporal gyri. *Schizophr Res.* 2006;87(1-3):116-126.
854 doi:10.1016/j.schres.2006.04.023
- 855 103. van Lutterveld R, van den Heuvel MP, Diederer KMJ, et al. Cortical thickness in
856 individuals with non-clinical and clinical psychotic symptoms. *Brain.* 2014;137(Pt
857 10):2664-2669. doi:10.1093/brain/awu167
- 858 104. Sasabayashi D, Takayanagi Y, Takahashi T, et al. Subcortical Brain Volume
859 Abnormalities in Individuals With an At-risk Mental State. *Schizophr Bull.* 2020;46(4):834-
860 845. doi:10.1093/schbul/sbaa011
- 861 105. Pontious A, Kowalczyk T, Englund C, Hevner RF. Role of intermediate progenitor cells in
862 cerebral cortex development. *Dev Neurosci.* 2008;30(1-3):24-32. doi:10.1159/000109848
- 863 106. Rakic P. Specification of cerebral cortical areas. *Science.* 1988;241(4862):170–176.
- 864 107. Grasby KL, Jahanshad N, Painter JN, et al. The genetic architecture of the human
865 cerebral cortex. *Science.* 2020;367(6484). doi:10.1126/science.aay6690
- 866 108. Huttenlocher PR. Synaptic density in human frontal cortex - developmental changes and
867 effects of aging. *Brain Res.* 1979;163(2):195-205. doi:10.1016/0006-8993(79)90349-4
- 868 109. Rakic P, Bourgeois JP, Eckenhoff MF, Zecevic N, Goldman-Rakic PS. Concurrent
869 overproduction of synapses in diverse regions of the primate cerebral cortex. *Science.*
870 1986;232(4747):232-235. doi:10.1126/science.3952506
- 871 110. Petanjek Z, Judas M, Kostović I, Uylings HBM. Lifespan alterations of basal dendritic
872 trees of pyramidal neurons in the human prefrontal cortex: a layer-specific pattern. *Cereb*
873 *Cortex.* 2008;18(4):915-929. doi:10.1093/cercor/bhm124
- 874 111. Natu VS, Gomez J, Barnett M, et al. Apparent thinning of human visual cortex during
875 childhood is associated with myelination. *Proc Natl Acad Sci U S A.* 2019;116(41):20750-
876 20759. doi:10.1073/pnas.1904931116
- 877 112. Pantelis C, Yücel M, Wood SJ, et al. Structural brain imaging evidence for multiple
878 pathological processes at different stages of brain development in schizophrenia.
879 *Schizophr Bull.* 2005;31(3):672-696. doi:10.1093/schbul/sbi034
- 880 113. Sun D, Stuart GW, Jenkinson M, et al. Brain surface contraction mapped in first-episode
881 schizophrenia: a longitudinal magnetic resonance imaging study. *Mol Psychiatry.*
882 2009;14(10):976-986. doi:10.1038/mp.2008.34
- 883 114. Sellgren CM, Gracias J, Watmuff B, et al. Increased synapse elimination by microglia in
884 schizophrenia patient-derived models of synaptic pruning. *Nat Neurosci.* 2019;22(3):374-
885 385. doi:10.1038/s41593-018-0334-7
- 886 115. Whitaker KJ, Vértes PE, Romero-Garcia R, et al. Adolescence is associated with

- 887 genomically patterned consolidation of the hubs of the human brain connectome. *Proc*
888 *Natl Acad Sci U S A*. 2016;113(32):9105-9110. doi:10.1073/pnas.1601745113
- 889 116. Parker N, Patel Y, Jackowski AP, et al. Assessment of Neurobiological Mechanisms of
890 Cortical Thinning During Childhood and Adolescence and Their Implications for
891 Psychiatric Disorders. *JAMA Psychiatry*. Published online June 17, 2020.
892 doi:10.1001/jamapsychiatry.2020.1495
- 893 117. Perkins DO, Olde Loohuis L, Barbee J, et al. Polygenic Risk Score Contribution to
894 Psychosis Prediction in a Target Population of Persons at Clinical High Risk. *Am J*
895 *Psychiatry*. 2020;177(2):155-163. doi:10.1176/appi.ajp.2019.18060721
- 896 118. Mei C, Nelson B, Hartmann J, Spooner R, McGorry PD. Chapter 4 - Transdiagnostic early
897 intervention, prevention, and prediction in psychiatry. In: Baune BT, ed. *Personalized*
898 *Psychiatry*. Academic Press; 2020:27-37. doi:10.1016/B978-0-12-813176-3.00004-3
- 899 119. McGorry PD, Hartmann JA, Spooner R, Nelson B. Beyond the “at risk mental state”
900 concept: transitioning to transdiagnostic psychiatry. *World Psychiatry*. 2018;17(2):133-
901 142. doi:10.1002/wps.20514
- 902 120. Dazzan P, Soulsby B, Mechelli A, et al. Volumetric abnormalities predating the onset of
903 schizophrenia and affective psychoses: an MRI study in subjects at ultrahigh risk of
904 psychosis. *Schizophr Bull*. 2012;38(5):1083-1091. doi:10.1093/schbul/sbr035
- 905 121. Ziermans TB, Schothorst PF, Schnack HG, et al. Progressive structural brain changes
906 during development of psychosis. *Schizophr Bull*. 2012;38(3):519-530.
907 doi:10.1093/schbul/sbq113
- 908 122. Walter A, Studerus E, Smieskova R, et al. Hippocampal volume in subjects at high risk of
909 psychosis: a longitudinal MRI study. *Schizophr Res*. 2012;142(1-3):217-222.
910 doi:10.1016/j.schres.2012.10.013
- 911 123. Valli I, Marquand AF, Mechelli A, et al. Identifying Individuals at High Risk of Psychosis:
912 Predictive Utility of Support Vector Machine using Structural and Functional MRI Data.
913 *Front Psychiatry*. 2016;7:52. doi:10.3389/fpsy.2016.00052
- 914

915 **Table and Figure Legends**

916

917 **Table 1.** Demographic descriptives for every site in HC and CHR, and CHR-PS+ and CHR-PS-.
918 The Ns for CHR-PS+ and CHR-PS- do not always sum to the sample CHR N because most
919 sites lose individuals to follow-up (CHR-UNK).

920

921 **Figure 1.** Effect sizes for mega-analysis of group and conversion status. **A.** Overview of effect
922 sizes for HC vs. CHR. The top row reflects the results of the overall generalized linear model. A
923 deeper purple color indicates a greater effect of group (HC vs. CHR) in this region. We
924 observed the greatest effects of group in cortical thickness measures. The second row indicates
925 the pairwise effect sizes for HC vs. CHR, in regions that were statistically significant ($q < 0.05$) in
926 the overall comparison (top row of **A.**). Regions that were not statistically significant in the
927 overall comparison are in gray. In comparison to HC, CHR exhibited lower cortical thickness
928 across the cortex. Red color indicates that HC has a larger value in comparison to CHR for this
929 region. **B.** Overview of effect sizes for HC vs. CHR-PS+ vs. CHR-PS-. The top row reflects the
930 results of the overall generalized linear model. A deeper purple color indicates a greater effect
931 of conversion status (HC vs. CHR-PS+ vs. CHR-PS-) in this region. The second and third rows
932 indicate the pairwise effect sizes for HC vs. CHR-PS+ and CHR-PS- vs. CHR-PS+, respectively.
933 Pairwise comparisons are presented in regions that were statistically significant ($q < 0.05$) in the
934 overall comparison (top row of **B.**). Regions that were not statistically significant in the overall
935 comparison are in gray. Regions that CHR-PS+ had lower cortical thickness in comparison to
936 HC and CHR-PS-, CHR-PS+ are highlighted in yellow. **C.** Bar graphs for regions in which CHR-
937 PS+ (pink) had lower CT in comparison to CHR-PS- (purple) and HC (green).




938


939 **Figure 2.** Age effects of regions that exhibited an effect of conversion status. HC are in green,
940 CHR-PS+ are pink, and CHR-PS- are purple. Each graph has a line of best fit for the effect of
941 age on the respective neuroimaging measures. Shading around the line indicates the standard
942 error. The bars underneath the age plots reflect the derivative of the slope, i.e., the rate of
943 change taking place at a particular age, scaled as a pseudo t -statistic, based on the posterior
944 simulation. Age effects are plotted for A. fusiform cortical thickness, B. paracentral cortical
945 thickness, and C. superior temporal cortical thickness.

946


947 **Figure 3.** Cortical thickness alterations in CHR-PS+, schizophrenia, and 22q.11DS **A.**
948 Magnitude of cortical thickness alterations for the three groups. Whole-brain cortical thickness
949 effect sizes were not reported for SZ and 22q.11DS in original publications; values shown are
950 the hemispheres with the smallest effect size. Colored bars represent standard error. **B.**
951 Spearman's rank correlations between cortical thickness alterations in CHR-PS+ and individuals
952 with schizophrenia (top) and 22q.11 DS with psychosis (bottom).

953









A Age vs. Fusiform Cortical Thickness



B Age vs. Paracentral Thickness




C Age vs. Superior Temporal Thickness



Age (years)

A



B




Table 1. Age and sex information for healthy controls (HC) and clinical high risk for psychosis (CHR) participants at each site

| Site | HC | | | | CHR | | | | CHR-PS+ | | | | CHR-PS- | | | | Transition Rate | Mean Follow-up Length (SD) |
|----------------|-----|-----|---------------|-----------|-----|-----|---------------|-----------|---------|-----|---------------|-----------|---------|-----|---------------|-----------|-----------------|----------------------------|
| | N | % F | Mean Age (SD) | Age Range | N | % F | Mean Age (SD) | Age Range | N | % F | Mean Age (SD) | Age Range | N | % F | Mean Age (SD) | Age Range | | |
| Amsterdam | 23 | 57 | 23.4 (2.8) | 19-32 | 16 | 62 | 23.6 (2.5) | 20-30 | 0 | • | • | • | 16 | 62 | 23.6 (2.5) | 20-30 | • | 24 (0) |
| Barcelona-HSJD | 44 | 41 | 15.6 (1.6) | 13-18 | 55 | 58 | 15.2 (1.6) | 11-18 | 7 | 43 | 15.7 (2.4) | 12-18 | 35 | 66 | 15.2 (1.5) | 11-18 | 16.7% | 17.4 (4.8) |
| Bern | 17 | 35 | 20.2 (6.1) | 13-34 | 43 | 51 | 18.5 (5.1) | 10-35 | 0 | • | • | • | 19 | 58 | 16.8 (3.8) | 10-26 | • | 15.8 (5.7) |
| Columbia1 | 9 | 22 | 24.4 (4.1) | 20-33 | 17 | 53 | 22.9 (5) | 15-31 | 3 | 67 | 19.4 (7.3) | 15-28 | 14 | 50 | 23.6 (4.3) | 16-31 | 17.6% | 20.6 (10.3) |
| Columbia2 | 15 | 60 | 26.2 (2.2) | 22-30 | 19 | 37 | 23.3 (3.6) | 18-31 | • | • | • | • | • | • | • | • | • | • |
| Columbia3 | 37 | 32 | 22.9 (3.6) | 15-30 | 58 | 26 | 21 (4) | 14-29 | 14 | 29 | 21.1 (4.8) | 15-29 | 44 | 25 | 20.9 (3.8) | 14-27 | 24.1% | 24 (0) |
| Copenhagen | 59 | 49 | 24.8 (3.3) | 20-35 | 163 | 53 | 24.2 (4.2) | 18-38 | 13 | 38 | 23.1 (3.4) | 18-29 | 95 | 57 | 24.5 (4.6) | 18-38 | 12% | 11.8 (1.2) |
| CSU | 59 | 42 | 21.5 (3.1) | 15-30 | 52 | 46 | 19.5 (5) | 13-35 | 21 | 57 | 19.4 (5.1) | 13-35 | 31 | 39 | 19.5 (5) | 13-30 | 40.4% | 14.7 (7.6) |
| Glasgow | 46 | 65 | 22.8 (3.6) | 18-32 | 80 | 79 | 22.2 (4.8) | 17-34 | 6 | 83 | 18.5 (1.9) | 17-22 | 74 | 78 | 22.5 (4.8) | 17-34 | 7.5% | 20.2 (9.9) |
| Heidelberg | 33 | 48 | 15.7 (0.9) | 14-17 | 22 | 59 | 15.1 (1.1) | 14-17 | 0 | • | • | • | 18 | 67 | 15.1 (1) | 14-17 | • | 9.7 (3.3) |
| IDIBAPS | 54 | 65 | 15.9 (1.6) | 11-18 | 74 | 66 | 15.3 (1.7) | 10-18 | 17 | 65 | 15.1 (1.4) | 13-17 | 42 | 67 | 15.5 (1.9) | 10-18 | 28.8% | 14.3 (5.5) |
| ISMMS | 12 | 42 | 27.9 (3.7) | 23-35 | 25 | 52 | 23.4 (5.4) | 17-35 | 1 | 0 | 26.3 (0) | 26-26 | 12 | 58 | 23.6 (5.5) | 17-35 | 7.7% | 6 (0) |
| London | 29 | 34 | 24.5 (4.7) | 20-36 | 81 | 31 | 22.6 (4.4) | 18-38 | 6 | 0 | 24 (4.4) | 18-29 | 62 | 32 | 22.3 (4.6) | 18-38 | 8.8% | 18.8 (8.7) |
| Maastricht | 38 | 32 | 25.6 (5.7) | 18-39 | 48 | 29 | 20.2 (4.1) | 12-29 | 6 | 33 | 20.5 (5.2) | 15-26 | 25 | 32 | 18.6 (3.4) | 12-27 | 19.4% | • |
| Melbourne | 92 | 46 | 21.9 (3.6) | 15-30 | 249 | 50 | 19.7 (3.4) | 14-29 | 71 | 44 | 19.5 (3.5) | 14-29 | 165 | 52 | 19.8 (3.4) | 14-28 | 30.1% | 71.4 (53.7) |
| Mexico City | 38 | 26 | 20.9 (3.4) | 15-28 | 33 | 21 | 19.5 (4.1) | 13-31 | 7 | 29 | 20.4 (6) | 15-31 | 26 | 19 | 19.3 (3.6) | 13-27 | 21.2% | 24 (0) |
| MHRC | 51 | 0 | 22.2 (2.8) | 16-27 | 38 | 0 | 20.1 (2.5) | 16-28 | 3 | 0 | 19 (2.4) | 16-21 | 35 | 0 | 20.2 (2.5) | 17-28 | 7.9% | 30.2 (6.6) |
| MPRC | 20 | 40 | 17.8 (4.3) | 12-24 | 31 | 52 | 17 (3.2) | 12-22 | 3 | 33 | 16 (4.4) | 13-21 | 10 | 50 | 15.8 (2.7) | 12-20 | 23.1% | 7.1 (1.1) |
| Newcastle | 17 | 76 | 20.3 (1.9) | 17-24 | 45 | 53 | 19.6 (2.2) | 15-24 | 1 | 0 | 17.4 (0) | 17-17 | 41 | 54 | 19.6 (2.2) | 15-24 | 2.4% | 21.5 (12) |
| Oslo Region | 63 | 38 | 19.8 (3.6) | 15-29 | 21 | 38 | 19.9 (3.6) | 16-29 | 2 | 50 | 20 (5.4) | 16-24 | 18 | 39 | 19.9 (3.7) | 16-29 | 10% | 12.5 (1.4) |
| Pitt | 65 | 40 | 23 (5.9) | 14-40 | 26 | 54 | 20.8 (5.3) | 12-36 | 2 | 50 | 17.1 (0.8) | 16-18 | 11 | 64 | 19.5 (6.4) | 12-36 | 15.4% | 13.1 (3.6) |
| RUMC | 29 | 66 | 23.9 (3.2) | 18-30 | 67 | 46 | 22.7 (3.9) | 16-30 | 4 | 50 | 24.5 (2.9) | 21-27 | 60 | 47 | 22.6 (3.9) | 16-30 | 6.2% | 8.3 (4.5) |
| Singapore | 53 | 47 | 22 (4.2) | 14-30 | 100 | 32 | 21.9 (3.6) | 14-30 | 11 | 27 | 20.1 (3.1) | 15-26 | 88 | 32 | 22.1 (3.6) | 14-30 | 11.1% | 18.9 (5.9) |
| SNUH | 74 | 32 | 21.2 (2.5) | 17-27 | 74 | 26 | 20.7 (3.8) | 15-34 | 9 | 33 | 22 (5) | 16-33 | 46 | 24 | 20.4 (3.7) | 15-34 | 16.4% | 30.9 (17.2) |
| Stavanger | 33 | 48 | 17 (3.1) | 13-27 | 37 | 59 | 16.6 (2.4) | 13-25 | 5 | 80 | 16.2 (2.7) | 13-19 | 31 | 58 | 16.7 (2.3) | 14-25 | 13.9% | 24 (0) |
| Toho | 16 | 50 | 23.2 (2.9) | 18-28 | 40 | 70 | 23.7 (6.9) | 13-39 | 4 | 75 | 19 (4.4) | 14-24 | 36 | 69 | 24.2 (7) | 13-39 | 10% | 12 (0) |
| Tokyo | 25 | 48 | 22.1 (2.8) | 16-25 | 39 | 46 | 20.9 (3.5) | 14-29 | 3 | 0 | 22.7 (4.7) | 19-28 | 25 | 60 | 20.5 (3.1) | 14-27 | 10.7% | 26.5 (12.1) |
| Toronto | 39 | 41 | 25.5 (5.2) | 18-38 | 27 | 44 | 20.8 (1.8) | 18-27 | 0 | • | • | • | 4 | 50 | 19.7 (1.1) | 18-21 | • | 24 (0) |
| Toyama | 141 | 48 | 25.1 (4.2) | 18-38 | 79 | 44 | 18.5 (4) | 13-31 | 10 | 30 | 20.8 (5.7) | 15-31 | 69 | 46 | 18.1 (3.7) | 13-30 | 12.7% | 37.4 (34.2) |
| UCSF | 103 | 42 | 23.7 (7.5) | 13-40 | 71 | 48 | 19.3 (4.4) | 12-32 | 13 | 38 | 21.4 (4.4) | 16-29 | 47 | 49 | 19 (4.1) | 12-29 | 21.7% | 21 (5.4) |
| Zurich | 43 | 51 | 22.2 (5.6) | 13-36 | 62 | 40 | 19.1 (4.9) | 13-35 | 11 | 18 | 18.5 (3.4) | 14-24 | 35 | 40 | 19.1 (5.3) | 13-35 | 23.9% | |

Follow-up times reported in months. “•” Indicates that data was not available, either because no CHR subjects transitioned to a psychotic disorder or follow-up data was not available. Site name abbreviations as follows: Amsterdam = Vrije Universiteit Amsterdam, The Netherlands; Barcelona-HSJD

= Hospital Sant Joan de Déu Barcelona, Barcelona, Spain; Bern = University Hospital of Child and Adolescent Psychiatry and Psychotherapy, University of Bern, Switzerland; Columbia1 = New York State Psychiatric Institute, Columbia University, USA; Columbia2 = New York State Psychiatric Institute, Columbia University, USA; Columbia3 = New York State Psychiatric Institute, Columbia University, USA; Copenhagen = Mental Health Center Copenhagen and CINS, Mental Health Center Glostrup, University of Copenhagen, Denmark; CSU = Central South University, China; Glasgow = Institute of Neuroscience and Psychology, University of Glasgow, Scotland; Heidelberg = Heidelberg University Hospital, Germany; IDIBAPS = August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain; ISMMS = Icahn School of Medicine at Mount Sinai, USA; London = Institute of Psychiatry, Psychology & Neuroscience, King's College London, UK; Maastricht = Maastricht University, The Netherlands; Melbourne = University of Melbourne, Australia; Mexico City = Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico; MHRC = Mental Health Research Center Moscow, Russia; MPRC = Maryland Psychiatric Research Center, University of Maryland School of Medicine, USA; Newcastle = University of Newcastle, Australia; Oslo Region = NORMENT, University of Oslo and Oslo University Hospital, Norway; Pitt = University of Pittsburgh, USA; RUMC = Rush University Medical Center, Chicago, IL USA; Singapore = Institute of Mental Health, Singapore and National University of Singapore, Singapore; SNUH = Seoul National University, South Korea; Stavanger = Stavanger University Hospital, Norway; Toho = Department of Neuropsychiatry, Toho University School of Medicine, Japan; Tokyo = Department of Neuropsychiatry, Graduate School of Medicine, The University of Tokyo; Toronto = Centre for Addiction and Mental Health, University of Toronto, Canada; Toyama = University of Toyama Graduate School of Medicine and Pharmaceutical Sciences, Japan; UCSF = University of California, San Francisco, USA; Zurich = Psychiatric Hospital, University of Zurich, Switzerland